CTMX

Cytomx Therapeutics Stock Analysis

AI Rating

Low
  • Quality9/10
  • Growth↓ 2/10
  • Value↓ 0/10
Cytomx Therapeutics sales and earnings growth
CTMX Growth
Fair
  • Revenue Y/Y↓ -44.82%
  • EPS Y/Y↓ -139.47%
  • FCF Y/Y↑ 12.40%
Cytomx Therapeutics gross and profit margin trends
CTMX Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -26.70%
  • ROIC 5Y↓ -188.88%
Cytomx Therapeutics net debt vs free cash flow
CTMX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Cytomx Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗